Barbara A. Gilchrest
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Barbara A. Gilchrest has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
Mark S. Eller
14 shared publicationsMina Yaar
10 shared publicationsM. Yaar
Department of Dermatology, Boston University School of Medicine, 609 Albany Street, Boston, MA 02118-2394, USA
4 shared publications- David A. Goukassian
Department of Dermatology, Boston University School of Medicine, Boston, MA 02118, USA
3 shared publications - Jag Bhawan
Dermatopathology Section, Department of Dermatology, Boston University School of Medicine, Boston, MA 02118, USA
3 shared publications - Vladimir A. Botchkarev
Department of Dermatology, Boston University School of Medicine
3 shared publications
Latest Publications
- 25 November 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (5) , 1177-1178
Response to Surber and Osterwalder
- 25 November 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (5) , 1177-1178
Response to Surber and Osterwalder
- Open Access
- 24 August 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (2) , 430-434.e1
Next-Generation Zinc Oxide–Based Sunscreens: Molecular Characteristics and Advantages
- 24 August 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (2) , 430-434.e1
Open AccessNext-Generation Zinc Oxide–Based Sunscreens: Molecular Characteristics and Advantages
- Open Access
- 11 April 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (8) , 1406-1411
Sunscreens: Misconceptions and Misinformation
- 11 April 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (8) , 1406-1411
Open AccessSunscreens: Misconceptions and Misinformation
- Open Access
- 6 October 2021
- Published by Wiley in Clinical Pharmacology in Drug Development
- Vol. 10 (10) , 1126-1129
Tirbanibulin: A New Topical Therapy for Actinic Keratoses With a Novel Mechanism of Action and Improved Ease of Use
- 6 October 2021
- Published by Wiley in Clinical Pharmacology in Drug Development
- Vol. 10 (10) , 1126-1129
Open AccessTirbanibulin: A New Topical Therapy for Actinic Keratoses With a Novel Mechanism of Action and Improved Ease of Use
- 1 April 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (4) , 727-731
Actinic Keratoses: Reconciling the Biology of Field Cancerization with Treatment Paradigms
- 1 April 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (4) , 727-731
Actinic Keratoses: Reconciling the Biology of Field Cancerization with Treatment Paradigms
- 16 October 2019
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 33 (10) , 1818-1820
Pioneers in Dermatology and Venereology: an interview with Prof. Barbara A. Gilchrest
- 16 October 2019
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 33 (10) , 1818-1820
Pioneers in Dermatology and Venereology: an interview with Prof. Barbara A. Gilchrest
- 1 September 2014
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 40 (9) , 979-987
Effective Blue Light Photodynamic Therapy Does Not Affect Cutaneous Langerhans Cell Number or Oxidatively Damage DNA
BACKGROUND Photodynamic therapy (PDT) using aminolevulinic acid (ALA) with blue light or red light is effective for treating actinic keratoses (AKs). However, immunosuppression follows red light PDT, raising the spectre of skin cancer promotion in treated skin. OBJECTIVE To determine whether broad-area short incubation (BASI)-ALA-PDT using blue light immunosuppression immunosuppresses treated skin. METHODS Patients were evaluated clinically and by standardized facial biopsies of non-AK skin before, 24 hours and 1 month after customary blue light BASI-ALA-PDT. All biopsies were stained for markers of epidermal atypia and Langerhans cells (LCs); and at 24 hours to detect oxidative DNA damage. RESULTS Patients had an 81% reduction in AKs and slight improvement in clinical and histologic signs of photoaging after 1 month. The biopsied chronically photodamaged skin without clinically detectable AKs showed no effect of PDT on the LC number, distribution, or morphology; and no oxidative DNA damage, in contrast to the changes reported after customary red light PDT. CONCLUSION Customary blue light BASI-ALA-PDT does not affect the LC number or produce oxidative DNA damage, the sequelae of red light PDT responsible for immunosuppression in treated skin.
- 1 September 2014
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 40 (9) , 979-987
Effective Blue Light Photodynamic Therapy Does Not Affect Cutaneous Langerhans Cell Number or Oxidatively Damage DNA
BACKGROUND Photodynamic therapy (PDT) using aminolevulinic acid (ALA) with blue light or red light is effective for treating actinic keratoses (AKs). However, immunosuppression follows red light PDT, raising the spectre of skin cancer promotion in treated skin. OBJECTIVE To determine whether broad-area short incubation (BASI)-ALA-PDT using blue light immunosuppression immunosuppresses treated skin. METHODS Patients were evaluated clinically and by standardized facial biopsies of non-AK skin before, 24 hours and 1 month after customary blue light BASI-ALA-PDT. All biopsies were stained for markers of epidermal atypia and Langerhans cells (LCs); and at 24 hours to detect oxidative DNA damage. RESULTS Patients had an 81% reduction in AKs and slight improvement in clinical and histologic signs of photoaging after 1 month. The biopsied chronically photodamaged skin without clinically detectable AKs showed no effect of PDT on the LC number, distribution, or morphology; and no oxidative DNA damage, in contrast to the changes reported after customary red light PDT. CONCLUSION Customary blue light BASI-ALA-PDT does not affect the LC number or produce oxidative DNA damage, the sequelae of red light PDT responsible for immunosuppression in treated skin.
- 1 November 2012
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 132 (11) , 2664-2666
Topical Application of Thymidine Dinucleotide to Newborn Mice Reduces and Delays Development of UV-Induced Melanomas
- 1 November 2012
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 132 (11) , 2664-2666
Topical Application of Thymidine Dinucleotide to Newborn Mice Reduces and Delays Development of UV-Induced Melanomas
- 1 September 2012
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 132 (9) , 2121-2122
Ode to Reviewers
- 1 September 2012
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 132 (9) , 2121-2122
Ode to Reviewers